MSD, known as Merck & Co in the US and Canada, said the studies' independent data monitoring committee had concluded that, after looking at the totality of the safety and efficacy data ...
Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... Koselgo/Koselugo (selumetinib), co-marketed by MSD, which was approved for NF1-PN in paediatric patients aged ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
